RxMP Therapeutics Secures $10.7 Million Contract for RMP-402 Development

SEATTLE, Oct. 20, 2026 /CourierPR/ -- RxMP Therapeutics, Inc., a late pre-clinical stage therapeutics company developing novel therapies for rapid control of hemorrhage and excessive bleeding, has secured a significant contract from the U.S. Department of War through the Defense Advanced Research Projects Agency (DARPA) under its Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) program. The company will receive up to $10.7 million to support the completion of IND-enabling development and manufacturing scale-up of RMP-402.

RMP-402 is a first-in-class hemostatic biomimetic composed of manufactured allogeneic red cell membrane particles, designed to rapidly accelerate hemostasis at sites of active bleeding without increasing the risk of off-target clotting. The product is being developed for use in both military and civilian settings, addressing a global trauma, medical, and surgical bleeding market estimated at up to $12 billion annually. Uncontrolled bleeding remains a leading cause of morbidity and preventable death, particularly in settings where conventional blood products are difficult or impossible to provide.

The award is part of DARPA's RAPIID program, which focuses on advancing shelf-stable blood analog technologies that can be manufactured at scale and rapidly progressed toward regulatory authorization. The program seeks to establish the manufacturing, clinical, commercial, and regulatory pathways necessary to make advanced hemorrhage countermeasures available to warfighters and civilians when traditional blood products are unavailable.

The award will fund the completion of RxMP's lead product candidate, RMP-402, including remaining IND-enabling development activities, furthering manufacturing scale-up, and preparation of the Investigational New Drug (IND) application package. This support is crucial for advancing RMP-402 toward first-in-human clinical development, with the potential for an Emergency Use Authorization for combat casualty care.

The contract will enable RxMP to address several of the most significant remaining preclinical, manufacturing, and regulatory milestones required to advance RMP-402 toward first-in-human clinical development. This support is expected to enhance the company's momentum and bring RMP-402 closer to regulatory review and potential commercialization.